<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881568</url>
  </required_header>
  <id_info>
    <org_study_id>TRANEX1</org_study_id>
    <nct_id>NCT01881568</nct_id>
  </id_info>
  <brief_title>Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA</brief_title>
  <acronym>TRANEX1</acronym>
  <official_title>Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the efficacy and safety of topical Tranexamic Acid (TA) to
      reduce the blood transfusion rate in total knee arthroplasty. The secondary endpoints are to
      estimate the visible blood loss at 24 hours after surgery, and invisible blood loss through
      serial counting of Hb/Htc. Methodology. TRANEX1 is a phase III, unicentric, controlled,
      randomized, double blind clinical trial that compare efficacy and safety of topical TA versus
      intravenous TA in a multimodal protocol, with no-inferiority criteria(n=79).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The groups will be compared by ITT and PP. The non-inferiority would be estimated by
      comparing the confidence interval using the traditional test, and Wilson test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood transfusion rate</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <description>Number of transfused patients in each arm/Total number of patients in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visible blood loss</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Number of milliliters drained in Redon after 24 hours post OP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invisible blood loss</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>Number of milliliters estimated with Nedler formula 48 hours after surgery. Invisible blood loss= 75*weight(Kg)*[(Hb0-Hb1)/Hb0]+ blood transfused(mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery infection rate</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Percent of patients with proved signs of infection during the hospital stay
Percent of patients with proved signs of infection one month after surgery(safety reasons)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of motion</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <description>- Range (in degrees) from full extension to full flexion during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of drug-related adverse events</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 5 days</time_frame>
    <description>Rate and characteristics of the adverse events during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of PE</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Percent of PE during the hospital stay
Percent of PE one month after surgery(safety reasons)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of DVT</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Percent of DVT during the hospital stay
Percent of DVT one month after surgery(safety reasons)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate or Thrombophlebitis</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Percent of Thrombophlebitis during the hospital stay
Percent of Thrombophlebitis one month after surgery(safety reasons)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:
50mL by irrigation before wound closure
50mL by intraarticular administration (Drenofast) after wound closure.
Intravenous administration of Normal saline (0.9% sodium chloride) as follow:
100mL before tourniquet realised
100mL 3 hours after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of Normal saline (0.9% sodium chloride) as follow:
50mL by irrigation before wound closure
50mL by intraarticular administration (Drenofast) after wound closure
Intravenous administration of two dosis of Tranexamic Acid as follow:
15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised
15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>AMCHAFIBRIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>AMCHAFIBRIN,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (greater than 18 years old)

          -  Patients scheduled for primary unilateral knee arthroplasty

          -  Patients for La Paz- Cantoblanco Hospital, Madrid, Spain

        Exclusion Criteria:

          -  Patients that refuse to sign the Inform Consent

          -  Allergy to tranexamic acid

          -  Major comorbidities: Severe ischemic heart disease(class III and IV of New York Heart
             Association); sleep apnea syndrome; severe EPOC; renal dysfunction (plasma
             creatinine&gt;2mg/dL if mens and &gt;1.8mg/dL if woman); or hepatic disfunction.

          -  Coagulopathy (preoperative platelet count &lt;150,000/mm3, INR&gt;1.4, prolonged PPT(&gt;1.4 x
             normal)

          -  History of thromboembolic disease: CVA, DVT, PE

          -  Blood dyscrasias

          -  Retinopathy (disturbances of color vision)

          -  Jehovah's witnesses

          -  Pregnancy

          -  Breastfeeding

          -  Been participating or been participated a year ago in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Gomez Barrena, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>Enrique GÃ³mez Barrena</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Total Knee Arthroplasty, TKA, blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 26, 2015</submitted>
    <returned>March 7, 2015</returned>
    <submitted>October 25, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

